Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data

A comprehensive approach to anticipating the progression of mild cognitive impairment

The immersive experience provided by our approach empowers researchers with an intuitive exploration of brain structures. Within the brain's central nervous system, encompassing both white and gray matter, symptoms associated with Alzheimer's disease (AD) often manifest through gray matter decline. The manual identification of these changes proves to be a time-intensive endeavor. Although learning-based systems can detect such changes, their implementation requires substantial computational resources and extensive datasets. To surmount these challenges, we present a tailored framework designed for the categorization of distinct AD stages through brain image tissue segmentation. Our innovative approach seamlessly integrates transfer learning and fine-tuning of frozen layers and employs models such as VGG16, VGG19, AlexNet, and ResNet50. This comprehensive strategy significantly amplifies simulation outcomes across five AD categories, contributing to an overall enhancement in model efficacy. In the initial stages, our model undergoes fine-tuning to predict various AD stages, and the integration of data augmentation techniques further refines its performance. Our study culminates with the assertion that a pre-trained model, characterized by deep connectivity of dense layers, additional layers, and frozen blocks, adeptly addresses the challenges intrinsic to the proposed multiclass classification. Experimental results conclusively endorse the superior accuracy achieved through the implementation of our proposed strategy.

Recent Advancements in Neuroimaging-Based Alzheimer's Disease Prediction Using Deep Learning Approaches in e-Health: A Systematic Review

Purpose

Alzheimer's disease (AD) is a severe neurological disease that significantly impairs brain function. Timely identification of AD is essential for appropriate treatment and care. This comprehensive review intends to examine current developments in deep learning (DL) approaches with neuroimaging for AD diagnosis, where popular imaging types, reviews well-known online accessible data sets, and describes different algorithms used in DL for the correct initial evaluation of AD are presented.

Significance

Conventional diagnostic techniques, including medical evaluations and cognitive assessments, usually not identify the initial stages of Alzheimer's. Neuroimaging methods, when integrated with DL techniques, have demonstrated considerable potential in enhancing the diagnosis and categorization of AD. DL models have received significant interest due to their capability to identify AD in its early phases automatically, which reduces the mortality rate and treatment cost of AD.

Method

An extensive literature search was performed in leading scientific databases, concentrating on papers published from 2021 to 2025. Research leveraging DL models on different neuroimaging techniques such as magnetic resonance imaging (MRI), positron emission tomography, and functional magnetic resonance imaging (fMRI), and so forth. The review complies with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

Current developments show that CNN-based techniques, especially those utilizing hybrid and transfer learning frameworks, outperform conventional DL methods. Research employing the combination of multimodal neuroimaging data has demonstrated enhanced diagnostic precision. Still, challenges such as method interpretability, data heterogeneity, and limited data exist as significant issues.

Conclusion

DL has considerably improved the accuracy and reliability of AD diagnosis with neuroimaging. Regardless of issues with data accessibility and adaptability, current studies into the interpretability of models and multimodal fusion provide potential for clinical application. Further research should concentrate on standardized data sets, rigorous validation architectures, and understandable AI methodologies to enhance the effectiveness of DL methods in AD prediction.

Deep generative models for physiological signals: A systematic literature review

In this paper, we present a systematic literature review on deep generative models for physiological signals, particularly electrocardiogram (ECG), electroencephalogram (EEG), photoplethysmogram (PPG) and electromyogram (EMG). Compared to the existing review papers, we present the first review that summarizes the recent state-of-the-art deep generative models. By analyzing the state-of-the-art research related to deep generative models along with their main applications and challenges, this review contributes to the overall understanding of these models applied to physiological signals. Additionally, by highlighting the employed evaluation protocol and the most used physiological databases, this review facilitates the assessment and benchmarking of deep generative models.

Advanced Artificial Intelligence Technologies Transforming Contemporary Pharmaceutical Research

One area of study within machine learning and artificial intelligence (AI) seeks to create computer programs with intelligence that can mimic human focal processes in order to produce results. This technique includes data collection, effective data usage system development, conclusion illustration, and arrangements. Analysis algorithms that are learning to mimic human cognitive activities are the most widespread application of AI. Artificial intelligence (AI) studies have proliferated, and the field is quickly beginning to understand its potential impact on medical services and investigation. This review delves deeper into the pros and cons of AI across the healthcare and pharmaceutical research industries. Research and review articles published throughout the last few years were selected from PubMed, Google Scholar, and Science Direct, using search terms like 'artificial intelligence', 'drug discovery', 'pharmacy research', 'clinical trial', etc. This article provides a comprehensive overview of how artificial intelligence (AI) is being used to diagnose diseases, treat patients digitally, find new drugs, and predict when outbreaks or pandemics may occur. In artificial intelligence, neural networks and deep learning are some of the most popular tools; in clinical research, Bayesian non-parametric approaches hold promise for better results, while smartphones and the processing of natural languages are employed in recognizing patients and trial monitoring. Seasonal flu, Ebola, Zika, COVID-19, tuberculosis, and outbreak predictions were made using deep computation and artificial intelligence. The academic world is hopeful that AI development will lead to more efficient and less expensive medical and pharmaceutical investigations and better public services.

Deep Learning Approaches for the Classification of Keloid Images in the Context of Malignant and Benign Skin Disorders

Background/Objectives: Misdiagnosing skin disorders leads to the administration of wrong treatments, sometimes with life-impacting consequences. Deep learning algorithms are becoming more and more used for diagnosis. While many skin cancer/lesion image classification studies focus on datasets containing dermatoscopic images and do not include keloid images, in this study, we focus on diagnosing keloid disorders amongst other skin lesions and combine two publicly available datasets containing non-dermatoscopic images: one dataset with keloid images and one with images of other various benign and malignant skin lesions (melanoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, seborrheic keratosis, and nevus). Methods: Different Convolution Neural Network (CNN) models are used to classify these disorders as either malignant or benign, to differentiate keloids amongst different benign skin disorders, and furthermore to differentiate keloids among other similar-looking malignant lesions. To this end, we use the transfer learning technique applied to nine different base models: the VGG16, MobileNet, InceptionV3, DenseNet121, EfficientNetB0, Xception, InceptionRNV2, EfficientNetV2L, and NASNetLarge. We explore and compare the results of these models using performance metrics such as accuracy, precision, recall, F1score, and AUC-ROC. Results: We show that the VGG16 model (after fine-tuning) performs the best in classifying keloid images among other benign and malignant skin lesion images, with the following keloid class performance: an accuracy of 0.985, precision of 1.0, recall of 0.857, F1 score of 0.922 and AUC-ROC value of 0.996. VGG16 also has the best overall average performance (over all classes) in terms of the AUC-ROC and the other performance metrics. Using this model, we further attempt to predict the identification of three new non-dermatoscopic anonymised clinical images, classifying them as either malignant, benign, or keloid, and in the process, we identify some issues related to the collection and processing of such images. Finally, we also show that the DenseNet121 model has the best performance when differentiating keloids from other malignant disorders that have similar clinical presentations. Conclusions: The study emphasised the potential use of deep learning algorithms (and their drawbacks), to identify and classify benign skin disorders such as keloids, which are not usually investigated via these approaches (as opposed to cancers), mainly due to lack of available data.

Multimodal Brain Growth Patterns: Insights from Canonical Correlation Analysis and Deep Canonical Correlation Analysis with Auto-Encoder

Today's advancements in neuroimaging have been pivotal in enhancing our understanding of brain development and function using various MRI techniques. This study utilizes images from T1-weighted imaging and diffusion-weighted imaging to identify gray matter and white matter coherent growth patterns within 2 years from 9-10-year-old participants in the Adolescent Brain Cognitive Development (ABCD) Study. The motivation behind this investigation lies in the need to comprehend the intricate processes of brain development during adolescence, a critical period characterized by significant cognitive maturation and behavioral change. While traditional methods like canonical correlation analysis (CCA) capture the linear interactions of brain regions, a deep canonical correlation analysis with an autoencoder (DCCAE) nonlinearly extracts brain patterns. The study involves a comparative analysis of changes in gray and white matter over two years, exploring their interrelation based on correlation scores, extracting significant features using both CCA and DCCAE methodologies, and finding an association between the extracted features with cognition and the Child Behavior Checklist. The results show that both CCA and DCCAE components identified similar brain regions associated with cognition and behavior, indicating that brain growth patterns over this two-year period are linear. The variance explained by CCA and DCCAE components for cognition and behavior suggests that brain growth patterns better account for cognitive maturation compared to behavioral changes. This research advances our understanding of neuroimaging analysis and provides valuable insights into the nuanced dynamics of brain development during adolescence.

Classification of neuroimaging data in Alzheimer's disease using particle swarm optimization: A systematic review

AIM

Particle swarm optimization (PSO) is an algorithm that involves the optimization of Non-linear and Multidimensional problems to reach the best solutions with minimal parameterization. This metaheuristic model has frequently been used in the Pathological domain. This optimization model has been used in diverse forms while predicting Alzheimer's disease. It is a robust algorithm that works on linear and multi-modal data while predicting Alzheimer's disease. PSO techniques have been in action for quite some time for detecting various diseases and this paper systematically reviews the papers on various kinds of PSO techniques.

METHODS

To perform the systematic review, PRISMA guidelines were followed and a Boolean search ("particle swarm optimization" OR "PSO") AND Neuroimaging AND (Alzheimer's disease prediction OR classification OR diagnosis) were performed. The query was run in 4-reputed databases: Google Scholar, Scopus, Science Direct, and Wiley publications.

RESULTS

For the final analysis, 10 papers were incorporated for qualitative and quantitative synthesis. PSO has shown a dominant character while handling the uni-modal as well as the multi-modal data while predicting the conversion from MCI to Alzheimer's. It can be seen from the table that almost all the 10 reviewed papers had MRI-driven data. The accuracy rate was accentuated while adding other modalities or Neurocognitive measures.

CONCLUSIONS

Through this algorithm, we are providing an opportunity to other researchers to compare this algorithm with other state-of-the-art algorithms, while seeing the classification accuracy, with the aim of early prediction and progression of MCI into Alzheimer's disease.

Generating synthetic past and future states of Knee Osteoarthritis radiographs using Cycle-Consistent Generative Adversarial Neural Networks

Knee Osteoarthritis (KOA), a leading cause of disability worldwide, is challenging to detect early due to subtle radiographic indicators. Diverse, extensive datasets are needed but are challenging to compile because of privacy, data collection limitations, and the progressive nature of KOA. However, a model capable of projecting genuine radiographs into different OA stages could augment data pools, enhance algorithm training, and offer pre-emptive prognostic insights. In this study, we developed a Cycle-Consistent Adversarial Network (CycleGAN) to generate synthetic past and future stages of KOA on any genuine radiograph. The model's effectiveness was validated through its impact on a KOA specialized Convolutional Neural Network (CNN). Transformations towards synthetic future disease states resulted in 83.76% of none-to-doubtful stage images being classified as moderate-to-severe stages, while retroactive transformations led to 75.61% of severe-stage images being classified as none-to-doubtful stages. Similarly, transformations from mild stages achieved 76.00% correct classification towards future stages and 69.00% for past stages. The CycleGAN demonstrated an exceptional ability to expand the knee joint space and eliminate bone-outgrowths (osteophytes), key radiographic indicators of disease progression. These results signify a promising potential for enhancing diagnostic models, data augmentation, and educational and prognostic uses. Nevertheless, further refinement, validation, and a broader evaluation process encompassing both CNN-based assessments and expert medical feedback are emphasized for future research and development.

Transformer-based approaches for neuroimaging: an in-depth review of their role in classification and regression tasks

In the ever-evolving landscape of deep learning (DL), the transformer model emerges as a formidable neural network architecture, gaining significant traction in neuroimaging-based classification and regression tasks. This paper presents an extensive examination of transformer's application in neuroimaging, surveying recent literature to elucidate its current status and research advancement. Commencing with an exposition on the fundamental principles and structures of the transformer model and its variants, this review navigates through the methodologies and experimental findings pertaining to their utilization in neuroimage classification and regression tasks. We highlight the transformer model's prowess in neuroimaging, showcasing its exceptional performance in classification endeavors while also showcasing its burgeoning potential in regression tasks. Concluding with an assessment of prevailing challenges and future trajectories, this paper proffers insights into prospective research directions. By elucidating the current landscape and envisaging future trends, this review enhances comprehension of transformer's role in neuroimaging tasks, furnishing valuable guidance for further inquiry.

Application of artificial intelligence in Alzheimer's disease: a bibliometric analysis

Background

Understanding how artificial intelligence (AI) is employed to predict, diagnose, and perform relevant analyses in Alzheimer's disease research is a rapidly evolving field. This study integrated and analyzed the relevant literature from the Science Citation Index (SCI) and Social Science Citation Index (SSCI) on the application of AI in Alzheimer's disease (AD), covering publications from 2004 to 2023.

Objective

This study aims to identify the key research hotspots and trends of the application of AI in AD over the past 20 years through a bibliometric analysis.

Methods

Using the Web of Science Core Collection database, we conducted a comprehensive visual analysis of literature on AI and AD published between January 1, 2004, and December 31, 2023. The study utilized Excel, Scimago Graphica, VOSviewer, and CiteSpace software to visualize trends in annual publications and the distribution of research by countries, institutions, journals, references, authors, and keywords related to this topic.

Results

A total of 2,316 papers were obtained through the research process, with a significant increase in publications observed since 2018, signaling notable growth in this field. The United States, China, and the United Kingdom made notable contributions to this research area. The University of London led in institutional productivity with 80 publications, followed by the University of California System with 74 publications. Regarding total publications, the Journal of Alzheimer's Disease was the most prolific while Neuroimage ranked as the most cited journal. Shen Dinggang was the top author in both total publications and average citations. Analysis of reference and keyword highlighted research hotspots, including the identification of various stages of AD, early diagnostic screening, risk prediction, and prediction of disease progression. The "task analysis" keyword emerged as a research frontier from 2021 to 2023.

Conclusion

Research on AI applications in AD holds significant potential for practical advancements, attracting increasing attention from scholars. Deep learning (DL) techniques have emerged as a key research focus for AD diagnosis. Future research will explore AI methods, particularly task analysis, emphasizing integrating multimodal data and utilizing deep neural networks. These approaches aim to identify emerging risk factors, such as environmental influences on AD onset, predict disease progression with high accuracy, and support the development of prevention strategies. Ultimately, AI-driven innovations will transform AD management from a progressive, incurable state to a more manageable and potentially reversible condition, thereby improving healthcare, rehabilitation, and long-term care solutions.

From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care

Background/Objectives: The dual forces of structured inquiry and serendipitous discovery have long shaped neuropsychiatric research, with groundbreaking treatments such as lithium and ketamine resulting from unexpected discoveries. However, relying on chance is becoming increasingly insufficient to address the rising prevalence of mental health disorders like depression and schizophrenia, which necessitate precise, innovative approaches. Emerging technologies like artificial intelligence, induced pluripotent stem cells, and multi-omics have the potential to transform this field by allowing for predictive, patient-specific interventions. Despite these advancements, traditional methodologies such as animal models and single-variable analyses continue to be used, frequently failing to capture the complexities of human neuropsychiatric conditions. Summary: This review critically evaluates the transition from serendipity to precision-based methodologies in neuropsychiatric research. It focuses on key innovations such as dynamic systems modeling and network-based approaches that use genetic, molecular, and environmental data to identify new therapeutic targets. Furthermore, it emphasizes the importance of interdisciplinary collaboration and human-specific models in overcoming the limitations of traditional approaches. Conclusions: We highlight precision psychiatry's transformative potential for revolutionizing mental health care. This paradigm shift, which combines cutting-edge technologies with systematic frameworks, promises increased diagnostic accuracy, reproducibility, and efficiency, paving the way for tailored treatments and better patient outcomes in neuropsychiatric care.

The potential role of machine learning and deep learning in differential diagnosis of Alzheimer's disease and FTD using imaging biomarkers: A review

INTRODUCTION

The prevalence of neurodegenerative diseases has significantly increased, necessitating a deeper understanding of their symptoms, diagnostic processes, and prevention strategies. Frontotemporal dementia (FTD) and Alzheimer's disease (AD) are two prominent neurodegenerative conditions that present diagnostic challenges due to overlapping symptoms. To address these challenges, experts utilize a range of imaging techniques, including magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), functional MRI (fMRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT). These techniques facilitate a detailed examination of the manifestations of these diseases. Recent research has demonstrated the potential of artificial intelligence (AI) in automating the diagnostic process, generating significant interest in this field.

MATERIALS AND METHODS

This narrative review aims to compile and analyze articles related to the AI-assisted diagnosis of FTD and AD. We reviewed 31 articles published between 2012 and 2024, with 23 focusing on machine learning techniques and 8 on deep learning techniques. The studies utilized features extracted from both single imaging modalities and multi-modal approaches, and evaluated the performance of various classification models.

RESULTS

Among the machine learning studies, Support Vector Machines (SVM) exhibited the most favorable performance in classifying FTD and AD. In deep learning studies, the ResNet convolutional neural network outperformed other networks.

CONCLUSION

This review highlights the utility of different imaging modalities as diagnostic aids in distinguishing between FTD and AD. However, it emphasizes the importance of incorporating clinical examinations and patient symptom evaluations to ensure comprehensive and accurate diagnoses.

ReIU: an efficient preliminary framework for Alzheimer patients based on multi-model data

The rising incidence of Alzheimer's disease (AD) poses significant challenges to traditional diagnostic methods, which primarily rely on neuropsychological assessments and brain MRIs. The advent of deep learning in medical diagnosis opens new possibilities for early AD detection. In this study, we introduce retinal vessel segmentation methods based on U-Net ad iterative registration Learning (ReIU), which extract retinal vessel maps from OCT angiography (OCT-A) facilities. Our method achieved segmentation accuracies of 79.1% on the DRIVE dataset, 68.3% on the HRF dataset. Utilizing a multimodal dataset comprising both healthy and AD subjects, ReIU extracted vascular density from fundus images, facilitating primary AD screening with a classification accuracy of 79%. These results demonstrate ReIU's substantial accuracy and its potential as an economical, non-invasive screening tool for Alzheimer's disease. This study underscores the importance of integrating multi-modal data and deep learning techniques in advancing the early detection and management of Alzheimer's disease.

A deep learning approach for non-invasive Alzheimer's monitoring using microwave radar data

Over 50 million people globally suffer from Alzheimer's disease (AD), emphasizing the need for efficient, early diagnostic tools. Traditional methods like Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans are expensive, bulky, and slow. Microwave-based techniques offer a cost-effective, non-invasive, and portable solution, diverging from conventional neuroimaging practices. This article introduces a deep learning approach for monitoring AD , using realistic numerical brain phantoms to simulate scattered signals via the CST Studio Suite. The obtained data is preprocessed using normalization, standardization, and outlier removal to ensure data integrity. Furthermore, we propose a novel data augmentation technique to enrich the dataset across various AD stages. Our deep learning approach combines Recursive Feature Elimination (RFE) with Principal Component Analysis (PCA) and Autoencoders (AE) for optimal feature selection. Convolution Neural Network (CNN) is combined with Gated Recurrent Unit (GRU), Bidirectional Long Short Term Memory (Bidirectional-LSTM), and Long Short-Term Memory (LSTM) to improve classification performance. The integration of RFE-PCA-AE significantly elevates performance, with the CNN+GRU model achieving an 87% accuracy rate, thus outperforming existing studies.

Magnetic resonance radiomics-based deep learning model for diagnosis of Alzheimer's disease

Introduction

The progression of Alzheimer's disease (AD) has been shown to significantly correlate with changes in brain tissue structure and leads to cognitive decline and dementia. Using radiomic features derived from brain magnetic resonance imaging (MRI) scan, we can get the help of deep learning (DL) model for diagnosing AD.

Methods

This study proposes the use of the DL model under the framework of MR radiomics for AD diagnosis. Two cross-racial independent cohorts from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (141 AD, 166 Mild Cognitive Impairment (MCI), and 231 normal control (NC) subjects) and Huashan hospital (45 AD, 35 MCI, and 31 NC subjects) were enrolled. We first performed preprocessing of MRI using methods such as spatial normalization and denoizing filtering. Next, we conducted Statistical Parametric Mapping analysis based on a two-sample t-test to identify regions of interest and extracted radiomic features using Radiomics tools. Subsequently, feature selection was carried out using the Least Absolute Shrinkage and Selection Operator model. Finally, the selected radiomic features were used to implement the AD diagnosis task with the TabNet model.

Results

The model was quantitatively evaluated using the average values obtained from five-fold cross-validation. In the three-way classification task, the model achieved classification average area under the curve (AUC) of 0.8728 and average accuracy (ACC) of 0.7111 for AD versus MCI versus NC. For the binary classification task, the average AUC values were 0.8778, 0.8864, and 0.9506 for AD versus MCI, MCI versus NC, and AD versus NC, respectively, with average ACC of 0.8667, 0.8556, and 0.9222 for these comparisons.

Conclusions

The proposed model exhibited excellent performance in the AD diagnosis task, accurately distinguishing different stages of AD. This confirms the value of MR DL radiomic model for AD diagnosis.

Early diagnosis of Alzheimer's disease and mild cognitive impairment using MRI analysis and machine learning algorithms

Early diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI) is crucial to prevent their progression. In this study, we proposed the analysis of magnetic resonance imaging (MRI) based on features including; hippocampus (HC) area size, HC grayscale statistics and texture features (mean, standard deviation, skewness, kurtosis, contrast, correlation, energy, homogeneity, entropy), lateral ventricle (LV) area size, gray matter area size, white matter area size, cerebrospinal fluid area size, patient age, weight, and cognitive score. Five machine learning classifiers; K-nearest neighborhood (KNN), support vector machine (SVM), random forest (RF), decision tree (DT), and multi-layer perception (MLP) were used to distinguish between groups: cognitively normal (CN) vs AD, early MCI (EMCI) vs late MCI (LMCI), CN vs EMCI, CN vs LMCI, AD vs EMCI, and AD vs LMCI. Additionally, the correlation and dependence were calculated to examine the strength and direction of association between each extracted feature and each classification of the group. The average classification accuracies in 20 trials were 95% (SVM), 71.50% (RF), 82.58% (RF), 84.91% (SVM), 85.83% (RF), and 85.08% (RF), respectively, with the best accuracies being 100% (SVM, RF, and MLP), 83.33% (RF), 91.66% (RF), 95% (SVM, and MLP), 96.66% (RF), and 93.33% (DT). Cognitive scores, HC and LV area sizes, and HC texture features demonstrated significant potential for diagnosing AD and its subtypes for all groups. RF and SVM showed better performance in distinguishing between groups. These findings highlight the importance of using 2D-MRI to identify key features containing critical information for early diagnosis of AD.

Supplementary Information

The online version contains supplementary material available at 10.1007/s42452-024-06440-w.

Artificial Intelligence-Based Methodologies for Early Diagnostic Precision and Personalized Therapeutic Strategies in Neuro-Ophthalmic and Neurodegenerative Pathologies

Advancements in neuroimaging, particularly diffusion magnetic resonance imaging (MRI) techniques and molecular imaging with positron emission tomography (PET), have significantly enhanced the early detection of biomarkers in neurodegenerative and neuro-ophthalmic disorders. These include Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. This review highlights the transformative role of advanced diffusion MRI techniques-Neurite Orientation Dispersion and Density Imaging and Diffusion Kurtosis Imaging-in identifying subtle microstructural changes in the brain and visual pathways that precede clinical symptoms. When integrated with artificial intelligence (AI) algorithms, these techniques achieve unprecedented diagnostic precision, facilitating early detection of neurodegeneration and inflammation. Additionally, next-generation PET tracers targeting misfolded proteins, such as tau and alpha-synuclein, along with inflammatory markers, enhance the visualization and quantification of pathological processes in vivo. Deep learning models, including convolutional neural networks and multimodal transformers, further improve diagnostic accuracy by integrating multimodal imaging data and predicting disease progression. Despite challenges such as technical variability, data privacy concerns, and regulatory barriers, the potential of AI-enhanced neuroimaging to revolutionize early diagnosis and personalized treatment in neurodegenerative and neuro-ophthalmic disorders is immense. This review underscores the importance of ongoing efforts to validate, standardize, and implement these technologies to maximize their clinical impact.

Differential risk of Alzheimer's disease in MCI subjects with elevated Abeta

BACKGROUNDS

People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease.

PURPOSE

The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data.

METHODS

The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol.

RESULTS

In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up.

DISCUSSION

Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.

The application of artificial intelligence in diagnosis of Alzheimer's disease: a bibliometric analysis

Alzheimer's disease (AD) is a neurodegenerative disorder that severely impacts cognitive function, posing significant physical and psychological burdens on patients and substantial economic challenges to families and society, particularly in aging populations where its prevalence is rising. Current diagnostic and therapeutic strategies, including pharmacological treatments and non-pharmacological interventions, exhibit considerable limitations in early diagnosis, etiological treatment, and disease management. This study aims to investigate the application of artificial intelligence (AI) in the early diagnosis and progression monitoring of AD through a bibliometric analysis of relevant literature. A systematic search in the Web of Science Core Collection identified 530 publications related to AI and AD, consisting of 361 original research articles and 169 review articles, with a notable increase in annual publication rates, particularly between 2019 and 2024. The United States and China emerged as leading contributors, emphasizing the importance of international collaboration. Institutional analysis revealed that Harvard University and Indiana University System are at the forefront, highlighting the role of academic institutions in fostering interdisciplinary research. Furthermore, the Journal of Alzheimer's Disease was identified as the most influential publication outlet. Key highly cited papers provided essential theoretical foundations for ongoing research. This study underscores the growing relevance of AI in AD research and suggests promising avenues for future investigations, particularly in enhancing diagnostic accuracy and therapeutic strategies through advanced data analytics and machine learning techniques.

Advances in artificial intelligence-based technologies for increasing the quality of medical products

Artificial intelligence (AI) is a technology that combines machine learning (ML) and deep learning. It has numerous usages in the domains of medicine and other sciences. Artificial intelligence can forecast the behavior of a drug's target protein and predict its desired physicochemical qualities. AI's potential to enhance healthcare services offerings formerly unheard-of opportunities for cost reserves, enhanced overall clinical and patient outcomes. The recent development of research in the biomedical field, encompassing fields such as genomics, computational medicine, AI, and algorithms for learning, has led to the demand for novel technology, a fresh workforce, and new standards of practice set the stage for the revolution in healthcare. By connecting these health statistics with cutting-edge AI technologies, precise insights into patient treatment can be obtained. Moreover, AI can aid in the search for new drugs by foretelling the target protein's two-dimensional structure. In the current review, an overview of the latest AI-based technologies and how they may be employed to reduce product development time to market and snowballing product quality, cost-effectiveness, as well as security throughout the manufacturing process is detailed.

Enhancement and evaluation for deep learning-based classification of volumetric neuroimaging with 3D-to-2D knowledge distillation

The application of deep learning techniques for the analysis of neuroimaging has been increasing recently. The 3D Convolutional Neural Network (CNN) technology, which is commonly adopted to encode volumetric information, requires a large number of datasets. However, due to the nature of the medical domain, there are limitations in the number of data available. This is because the cost of acquiring imaging is expensive and the use of personnel to annotate diagnostic labels is resource-intensive. For these reasons, several prior studies have opted to use comparatively lighter 2D CNNs instead of the complex 3D CNN technology. They analyze using projected 2D datasets created from representative slices extracted from 3D volumetric imaging. However, this approach, by selecting only projected 2D slices from the entire volume, reflects only partial volumetric information. This poses a risk of developing lesion diagnosis systems without a deep understanding of the interrelations among volumetric data. We propose a novel 3D-to-2D knowledge distillation framework that utilizes not only the projected 2D dataset but also the original 3D volumetric imaging dataset. This framework is designed to employ volumetric prior knowledge in training 2D CNNs. Our proposed method includes three modules: (i) a 3D teacher network that encodes volumetric prior knowledge from the 3D dataset, (ii) a 2D student network that encodes partial volumetric information from the 2D dataset, and aims to develop an understanding of the original volumetric imaging, and (iii) a distillation loss introduced to reduce the gap in the graph representation expressing the relationship between data in the feature embedding spaces of (i) and (ii), thereby enhancing the final performance. The effectiveness of our proposed method is demonstrated by improving the classification performance orthogonally across various 2D projection methods on two datasets from the 123I-DaTscan SPECT and 18 F-AV133 PET from Parkinson's Progression Markers Initiative (PPMI). Notably, when our approach is applied to the FuseMe approach, it achieves an F1 score of 98.30%, which is higher than that of the 3D teacher network (97.66%).

NeuroGraph: Benchmarks for Graph Machine Learning in Brain Connectomics

Machine learning provides a valuable tool for analyzing high-dimensional functional neuroimaging data, and is proving effective in predicting various neurological conditions, psychiatric disorders, and cognitive patterns. In functional magnetic resonance imaging (MRI) research, interactions between brain regions are commonly modeled using graph-based representations. The potency of graph machine learning methods has been established across myriad domains, marking a transformative step in data interpretation and predictive modeling. Yet, despite their promise, the transposition of these techniques to the neuroimaging domain has been challenging due to the expansive number of potential preprocessing pipelines and the large parameter search space for graph-based dataset construction. In this paper, we introduce NeuroGraph, a collection of graph-based neuroimaging datasets, and demonstrated its utility for predicting multiple categories of behavioral and cognitive traits. We delve deeply into the dataset generation search space by crafting 35 datasets that encompass static and dynamic brain connectivity, running in excess of 15 baseline methods for benchmarking. Additionally, we provide generic frameworks for learning on both static and dynamic graphs. Our extensive experiments lead to several key observations. Notably, using correlation vectors as node features, incorporating larger number of regions of interest, and employing sparser graphs lead to improved performance. To foster further advancements in graph-based data driven neuroimaging analysis, we offer a comprehensive open-source Python package that includes the benchmark datasets, baseline implementations, model training, and standard evaluation.

AI for the prediction of early stages of Alzheimer's disease from neuroimaging biomarkers - A narrative review of a growing field

OBJECTIVES

The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD diagnosis, prognosis, and management.

METHODS

We conducted a narrative review of studies using AI techniques applied to neuroimaging data for early AD prediction. We examined single-modality studies using structural MRI and PET imaging, as well as multi-modality studies integrating multiple neuroimaging techniques and biomarkers. Furthermore, they reviewed longitudinal studies that model AD progression and identify individuals at risk of rapid decline.

RESULTS

Single-modality studies using structural MRI and PET imaging have demonstrated high accuracy in classifying AD and predicting progression from mild cognitive impairment (MCI) to AD. Multi-modality studies, integrating multiple neuroimaging techniques and biomarkers, have shown improved performance and robustness compared to single-modality approaches. Longitudinal studies have highlighted the value of AI in modeling AD progression and identifying individuals at risk of rapid decline. However, challenges remain in data standardization, model interpretability, generalizability, clinical integration, and ethical considerations.

CONCLUSION

AI techniques applied to neuroimaging data have the potential to improve early AD diagnosis, prognosis, and management. Addressing challenges related to data standardization, model interpretability, generalizability, clinical integration, and ethical considerations is crucial for realizing the full potential of AI in AD research and clinical practice. Collaborative efforts among researchers, clinicians, and regulatory agencies are needed to develop reliable, robust, and ethical AI tools that can benefit AD patients and society.

Artificial intelligence in healthcare: a mastery

There is a vast development of artificial intelligence (AI) in recent years. Computational technology, digitized data collection and enormous advancement in this field have allowed AI applications to penetrate the core human area of specialization. In this review article, we describe current progress achieved in the AI field highlighting constraints on smooth development in the field of medical AI sector, with discussion of its implementation in healthcare from a commercial, regulatory and sociological standpoint. Utilizing sizable multidimensional biological datasets that contain individual heterogeneity in genomes, functionality and milieu, precision medicine strives to create and optimize approaches for diagnosis, treatment methods and assessment. With the arise of complexity and expansion of data in the health-care industry, AI can be applied more frequently. The main application categories include indications for diagnosis and therapy, patient involvement and commitment and administrative tasks. There has recently been a sharp rise in interest in medical AI applications due to developments in AI software and technology, particularly in deep learning algorithms and in artificial neural network (ANN). In this overview, we enlisted the major categories of issues that AI systems are ideally equipped to resolve followed by clinical diagnostic tasks. It also includes a discussion of the future potential of AI, particularly for risk prediction in complex diseases, and the difficulties, constraints and biases that must be meticulously addressed for the effective delivery of AI in the health-care sector.

Artificial General Intelligence for the Detection of Neurodegenerative Disorders

Parkinson's disease and Alzheimer's disease are among the most common neurodegenerative disorders. These diseases are correlated with advancing age and are hence increasingly becoming prevalent in developed countries due to an increasingly aging demographic. Several tools are used to predict and diagnose these diseases, including pathological and genetic tests, radiological scans, and clinical examinations. Artificial intelligence is evolving to artificial general intelligence, which mimics the human learning process. Large language models can use an enormous volume of online and offline resources to gain knowledge and use it to perform different types of tasks. This work presents an understanding of two major neurodegenerative disorders, artificial general intelligence, and the efficacy of using artificial general intelligence in detecting and predicting these neurodegenerative disorders. A detailed discussion on detecting these neurodegenerative diseases using artificial general intelligence by analyzing diagnostic data is presented. An Internet of Things-based ubiquitous monitoring and treatment framework is presented. An outline for future research opportunities based on the challenges in this area is also presented.

Early diagnosis of Alzheimer's disease using a group self-calibrated coordinate attention network based on multimodal MRI

Convolutional neural networks (CNNs) for extracting structural information from structural magnetic resonance imaging (sMRI), combined with functional magnetic resonance imaging (fMRI) and neuropsychological features, has emerged as a pivotal tool for early diagnosis of Alzheimer's disease (AD). However, the fixed-size convolutional kernels in CNNs have limitations in capturing global features, reducing the effectiveness of AD diagnosis. We introduced a group self-calibrated coordinate attention network (GSCANet) designed for the precise diagnosis of AD using multimodal data, including encompassing Haralick texture features, functional connectivity, and neuropsychological scores. GSCANet utilizes a parallel group self-calibrated module to enhance original spatial features, expanding the field of view and embedding spatial data into channel information through a coordinate attention module, which ensures long-term contextual interaction. In a four-classification comparison (AD vs. early MCI (EMCI) vs. late MCI (LMCI) vs. normal control (NC)), GSCANet demonstrated an accuracy of 78.70%. For the three-classification comparison (AD vs. MCI vs. NC), it achieved an accuracy of 83.33%. Moreover, our method exhibited impressive accuracies in the AD vs. NC (92.81%) and EMCI vs. LMCI (84.67%) classifications. GSCANet improves classification performance at different stages of AD by employing group self-calibrated to expand features receptive field and integrating coordinated attention to facilitate significant interactions among channels and spaces. Providing insights into AD mechanisms and showcasing scalability for various disease predictions.

Decoding the application of deep learning in neuroscience: a bibliometric analysis

The application of deep learning in neuroscience holds unprecedented potential for unraveling the complex dynamics of the brain. Our bibliometric analysis, spanning from 2012 to 2023, delves into the integration of deep learning in neuroscience, shedding light on the evolutionary trends and identifying pivotal research hotspots. Through the examination of 421 articles, this study unveils a significant growth in interdisciplinary research, marked by the burgeoning application of deep learning techniques in understanding neural mechanisms and addressing neurological disorders. Central to our findings is the critical role of classification algorithms, models, and neural networks in advancing neuroscience, highlighting their efficacy in interpreting complex neural data, simulating brain functions, and translating theoretical insights into practical diagnostics and therapeutic interventions. Additionally, our analysis delineates a thematic evolution, showcasing a shift from foundational methodologies toward more specialized and nuanced approaches, particularly in areas like EEG analysis and convolutional neural networks. This evolution reflects the field's maturation and its adaptation to technological advancements. The study further emphasizes the importance of interdisciplinary collaborations and the adoption of cutting-edge technologies to foster innovation in decoding the cerebral code. The current study provides a strategic roadmap for future explorations, urging the scientific community toward areas ripe for breakthrough discoveries and practical applications. This analysis not only charts the past and present landscape of deep learning in neuroscience but also illuminates pathways for future research, underscoring the transformative impact of deep learning on our understanding of the brain.

An interpretable deep learning framework identifies proteomic drivers of Alzheimer's disease

Alzheimer's disease (AD) is the leading neurodegenerative pathology in aged individuals, but many questions remain on its pathogenesis, and a cure is still not available. Recent research efforts have generated measurements of multiple omics in individuals that were healthy or diagnosed with AD. Although machine learning approaches are well-suited to handle the complexity of omics data, the models typically lack interpretability. Additionally, while the genetic landscape of AD is somewhat more established, the proteomic landscape of the diseased brain is less well-understood. Here, we establish a deep learning method that takes advantage of an ensemble of autoencoders (AEs) - EnsembleOmicsAE-to reduce the complexity of proteomics data into a reduced space containing a small number of latent features. We combine brain proteomic data from 559 individuals across three AD cohorts and demonstrate that the ensemble autoencoder models generate stable latent features which are well-suited for downstream biological interpretation. We present an algorithm to calculate feature importance scores based on the iterative scrambling of individual input features (i.e., proteins) and show that the algorithm identifies signaling modules (AE signaling modules) that are significantly enriched in protein-protein interactions. The molecular drivers of AD identified within the AE signaling modules derived with EnsembleOmicsAE were missed by linear methods, including integrin signaling and cell adhesion. Finally, we characterize the relationship between the AE signaling modules and the age of death of the patients and identify a differential regulation of vimentin and MAPK signaling in younger compared with older AD patients.

Progress and trends in neurological disorders research based on deep learning

In recent years, deep learning (DL) has emerged as a powerful tool in clinical imaging, offering unprecedented opportunities for the diagnosis and treatment of neurological disorders (NDs). This comprehensive review explores the multifaceted role of DL techniques in leveraging vast datasets to advance our understanding of NDs and improve clinical outcomes. Beginning with a systematic literature review, we delve into the utilization of DL, particularly focusing on multimodal neuroimaging data analysis-a domain that has witnessed rapid progress and garnered significant scientific interest. Our study categorizes and critically analyses numerous DL models, including Convolutional Neural Networks (CNNs), LSTM-CNN, GAN, and VGG, to understand their performance across different types of Neurology Diseases. Through particular analysis, we identify key benchmarks and datasets utilized in training and testing DL models, shedding light on the challenges and opportunities in clinical neuroimaging research. Moreover, we discuss the effectiveness of DL in real-world clinical scenarios, emphasizing its potential to revolutionize ND diagnosis and therapy. By synthesizing existing literature and describing future directions, this review not only provides insights into the current state of DL applications in ND analysis but also covers the way for the development of more efficient and accessible DL techniques. Finally, our findings underscore the transformative impact of DL in reshaping the landscape of clinical neuroimaging, offering hope for enhanced patient care and groundbreaking discoveries in the field of neurology. This review paper is beneficial for neuropathologists and new researchers in this field.

Frontiers and hotspots evolution in mild cognitive impairment: a bibliometric analysis of from 2013 to 2023

Background

Mild cognitive impairment is a heterogeneous syndrome. The heterogeneity of the syndrome and the absence of consensus limited the advancement of MCI. The purpose of our research is to create a visual framework of the last decade, highlight the hotspots of current research, and forecast the most fruitful avenues for future MCI research.

Methods

We collected all the MCI-related literature published between 1 January 2013, and 24 April 2023, on the "Web of Science." The visual graph was created by the CiteSpace and VOSviewer. The current research hotspots and future research directions are summarized through the analysis of keywords and co-cited literature.

Results

There are 6,075 articles were included in the final analysis. The number of publications shows an upward trend, especially after 2018. The United States and the University of California System are the most prolific countries and institutions, respectively. Petersen is the author who ranks first in terms of publication volume and influence. Journal of Alzheimer's Disease was the most productive journal. "neuroimaging," "fluid markers," and "predictors" are the focus of current research, and "machine learning," "electroencephalogram," "deep learning," and "blood biomarkers" are potential research directions in the future.

Conclusion

The cognition of MCI has been continuously evolved and renewed by multiple countries' joint efforts in the past decade. Hotspots for current research are on diagnostic biomarkers, such as fluid markers, neuroimaging, and so on. Future hotspots might be focused on the best prognostic and diagnostic models generated by machine learning and large-scale screening tools such as EEG and blood biomarkers.

Mining Alzheimer's disease clinical data: reducing effects of natural aging for predicting progression and identifying subtypes

Introduction

Because Alzheimer's disease (AD) has significant heterogeneity in encephalatrophy and clinical manifestations, AD research faces two critical challenges: eliminating the impact of natural aging and extracting valuable clinical data for patients with AD.

Methods

This study attempted to address these challenges by developing a novel machine-learning model called tensorized contrastive principal component analysis (T-cPCA). The objectives of this study were to predict AD progression and identify clinical subtypes while minimizing the influence of natural aging.

Results

We leveraged a clinical variable space of 872 features, including almost all AD clinical examinations, which is the most comprehensive AD feature description in current research. T-cPCA yielded the highest accuracy in predicting AD progression by effectively minimizing the confounding effects of natural aging.

Discussion

The representative features and pathogenic circuits of the four primary AD clinical subtypes were discovered. Confirmed by clinical doctors in Tangdu Hospital, the plaques (18F-AV45) distribution of typical patients in the four clinical subtypes are consistent with representative brain regions found in four AD subtypes, which further offers novel insights into the underlying mechanisms of AD pathogenesis.

Mapping Knowledge Landscapes and Emerging Trends in AI for Dementia Biomarkers: Bibliometric and Visualization Analysis

BACKGROUND

With the rise of artificial intelligence (AI) in the field of dementia biomarker research, exploring its current developmental trends and research focuses has become increasingly important. This study, using literature data mining, analyzes and assesses the key contributions and development scale of AI in dementia biomarker research.

OBJECTIVE

The aim of this study was to comprehensively evaluate the current state, hot topics, and future trends of AI in dementia biomarker research globally.

METHODS

This study thoroughly analyzed the literature in the application of AI to dementia biomarkers across various dimensions, such as publication volume, authors, institutions, journals, and countries, based on the Web of Science Core Collection. In addition, scales, trends, and potential connections between AI and biomarkers were extracted and deeply analyzed through multiple expert panels.

RESULTS

To date, the field includes 1070 publications across 362 journals, involving 74 countries and 1793 major research institutions, with a total of 6455 researchers. Notably, 69.41% (994/1432) of the researchers ceased their studies before 2019. The most prevalent algorithms used are support vector machines, random forests, and neural networks. Current research frequently focuses on biomarkers such as imaging biomarkers, cerebrospinal fluid biomarkers, genetic biomarkers, and blood biomarkers. Recent advances have highlighted significant discoveries in biomarkers related to imaging, genetics, and blood, with growth in studies on digital and ophthalmic biomarkers.

CONCLUSIONS

The field is currently in a phase of stable development, receiving widespread attention from numerous countries, institutions, and researchers worldwide. Despite this, stable clusters of collaborative research have yet to be established, and there is a pressing need to enhance interdisciplinary collaboration. Algorithm development has shown prominence, especially the application of support vector machines and neural networks in imaging studies. Looking forward, newly discovered biomarkers are expected to undergo further validation, and new types, such as digital biomarkers, will garner increased research interest and attention.

Revolutionizing early Alzheimer's disease and mild cognitive impairment diagnosis: a deep learning MRI meta-analysis

BACKGROUND

 The early diagnosis of Alzheimer's disease (AD) and mild cognitive impairment (MCI) remains a significant challenge in neurology, with conventional methods often limited by subjectivity and variability in interpretation. Integrating deep learning with artificial intelligence (AI) in magnetic resonance imaging (MRI) analysis emerges as a transformative approach, offering the potential for unbiased, highly accurate diagnostic insights.

OBJECTIVE

 A meta-analysis was designed to analyze the diagnostic accuracy of deep learning of MRI images on AD and MCI models.

METHODS

 A meta-analysis was performed across PubMed, Embase, and Cochrane library databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, focusing on the diagnostic accuracy of deep learning. Subsequently, methodological quality was assessed using the QUADAS-2 checklist. Diagnostic measures, including sensitivity, specificity, likelihood ratios, diagnostic odds ratio, and area under the receiver operating characteristic curve (AUROC) were analyzed, alongside subgroup analyses for T1-weighted and non-T1-weighted MRI.

RESULTS

 A total of 18 eligible studies were identified. The Spearman correlation coefficient was -0.6506. Meta-analysis showed that the combined sensitivity and specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.84, 0.86, 6.0, 0.19, and 32, respectively. The AUROC was 0.92. The quiescent point of hierarchical summary of receiver operating characteristic (HSROC) was 3.463. Notably, the images of 12 studies were acquired by T1-weighted MRI alone, and those of the other 6 were gathered by non-T1-weighted MRI alone.

CONCLUSION

 Overall, deep learning of MRI for the diagnosis of AD and MCI showed good sensitivity and specificity and contributed to improving diagnostic accuracy.

Long Non-Coding RNAs and Alzheimer's Disease: Towards Personalized Diagnosis

Alzheimer's disease (AD), a neurodegenerative disorder characterized by progressive cognitive decline, is the most common form of dementia. Currently, there is no single test that can diagnose AD, especially in understudied populations and developing countries. Instead, diagnosis is based on a combination of medical history, physical examination, cognitive testing, and brain imaging. Exosomes are extracellular nanovesicles, primarily composed of RNA, that participate in physiological processes related to AD pathogenesis such as cell proliferation, immune response, and neuronal and cardiovascular function. However, the identification and understanding of the potential role of long non-coding RNAs (lncRNAs) in AD diagnosis remain largely unexplored. Here, we clinically, cognitively, and genetically characterized a sample of 15 individuals diagnosed with AD (cases) and 15 controls from Barranquilla, Colombia. Advanced bioinformatics, analytics and Machine Learning (ML) techniques were used to identify lncRNAs differentially expressed between cases and controls. The expression of 28,909 lncRNAs was quantified. Of these, 18 were found to be differentially expressed and harbored in pivotal genes related to AD. Two lncRNAs, ENST00000608936 and ENST00000433747, show promise as diagnostic markers for AD, with ML models achieving > 95% sensitivity, specificity, and accuracy in both the training and testing datasets. These findings suggest that the expression profiles of lncRNAs could significantly contribute to advancing personalized AD diagnosis in this community, offering promising avenues for early detection and follow-up.

Connectional-style-guided contextual representation learning for brain disease diagnosis

Structural magnetic resonance imaging (sMRI) has shown great clinical value and has been widely used in deep learning (DL) based computer-aided brain disease diagnosis. Previous DL-based approaches focused on local shapes and textures in brain sMRI that may be significant only within a particular domain. The learned representations are likely to contain spurious information and have poor generalization ability in other diseases and datasets. To facilitate capturing meaningful and robust features, it is necessary to first comprehensively understand the intrinsic pattern of the brain that is not restricted within a single data/task domain. Considering that the brain is a complex connectome of interlinked neurons, the connectional properties in the brain have strong biological significance, which is shared across multiple domains and covers most pathological information. In this work, we propose a connectional style contextual representation learning model (CS-CRL) to capture the intrinsic pattern of the brain, used for multiple brain disease diagnosis. Specifically, it has a vision transformer (ViT) encoder and leverages mask reconstruction as the proxy task and Gram matrices to guide the representation of connectional information. It facilitates the capture of global context and the aggregation of features with biological plausibility. The results indicate that CS-CRL achieves superior accuracy in multiple brain disease diagnosis tasks across six datasets and three diseases and outperforms state-of-the-art models. Furthermore, we demonstrate that CS-CRL captures more brain-network-like properties, and better aggregates features, is easier to optimize, and is more robust to noise, which explains its superiority in theory.

Predicting Alzheimer's Disease Progression Using a Versatile Sequence-Length-Adaptive Encoder-Decoder LSTM Architecture

Detecting Alzheimer's disease (AD) accurately at an early stage is critical for planning and implementing disease-modifying treatments that can help prevent the progression to severe stages of the disease. In the existing literature, diagnostic test scores and clinical status have been provided for specific time points, and predicting the disease progression poses a significant challenge. However, few studies focus on longitudinal data to build deep-learning models for AD detection. These models are not stable to be relied upon in real medical settings due to a lack of adaptive training and testing. We aim to predict the individual's diagnostic status for the next six years in an adaptive manner where prediction performance improves with the number of patient visits. This study presents a Sequence-Length Adaptive Encoder-Decoder Long Short-Term Memory (SLA-ED LSTM) deep-learning model on longitudinal data obtained from the Alzheimer's Disease Neuroimaging Initiative archive. In the suggested approach, decoder LSTM dynamically adjusts to accommodate variations in training sequence length and inference length rather than being constrained to a fixed length. We evaluated the model performance for various sequence lengths and found that for inference length one, sequence length nine gives the highest average test accuracy and area under the receiver operating characteristic curves of 0.920 and 0.982, respectively. This insight suggests that data from nine visits effectively captures meaningful cognitive status changes and is adequate for accurate model training. We conducted a comparative analysis of the proposed model against state-of-the-art methods, revealing a significant improvement in disease progression prediction over the previous methods.

ArcheD, a residual neural network for prediction of cerebrospinal fluid amyloid-beta from amyloid PET images

Detection and measurement of amyloid-beta (Aβ) in the brain is a key factor for early identification and diagnosis of Alzheimer's disease (AD). We aimed to develop a deep learning model to predict Aβ cerebrospinal fluid (CSF) concentration directly from amyloid PET images, independent of tracers, brain reference regions or preselected regions of interest. We used 1870 Aβ PET images and CSF measurements to train and validate a convolutional neural network ("ArcheD"). We evaluated the ArcheD performance in relation to episodic memory and the standardized uptake value ratio (SUVR) of cortical Aβ. We also compared the brain region's relevance for the model's CSF prediction within clinical-based and biological-based classifications. ArcheD-predicted Aβ CSF values correlated with measured Aβ CSF values (r = 0.92; q < 0.01), SUVR (rAV45 = -0.64, rFBB = -0.69; q < 0.01) and episodic memory measures (0.33 < r < 0.44; q < 0.01). For both classifications, cerebral white matter significantly contributed to CSF prediction (q < 0.01), specifically in non-symptomatic and early stages of AD. However, in late-stage disease, the brain stem, subcortical areas, cortical lobes, limbic lobe and basal forebrain made more significant contributions (q < 0.01). Considering cortical grey matter separately, the parietal lobe was the strongest predictor of CSF amyloid levels in those with prodromal or early AD, while the temporal lobe played a more crucial role for those with AD. In summary, ArcheD reliably predicted Aβ CSF concentration from Aβ PET scans, offering potential clinical utility for Aβ level determination.

The power of many brains: Catalyzing neuropsychiatric discovery through open neuroimaging data and large-scale collaboration

Recent advances in open neuroimaging data are enhancing our comprehension of neuropsychiatric disorders. By pooling images from various cohorts, statistical power has increased, enabling the detection of subtle abnormalities and robust associations, and fostering new research methods. Global collaborations in imaging have furthered our knowledge of the neurobiological foundations of brain disorders and aided in imaging-based prediction for more targeted treatment. Large-scale magnetic resonance imaging initiatives are driving innovation in analytics and supporting generalizable psychiatric studies. We also emphasize the significant role of big data in understanding neural mechanisms and in the early identification and precise treatment of neuropsychiatric disorders. However, challenges such as data harmonization across different sites, privacy protection, and effective data sharing must be addressed. With proper governance and open science practices, we conclude with a projection of how large-scale imaging resources and collaborations could revolutionize diagnosis, treatment selection, and outcome prediction, contributing to optimal brain health.

UltraAIGenomics: Artificial Intelligence-Based Cardiovascular Disease Risk Assessment by Fusion of Ultrasound-Based Radiomics and Genomics Features for Preventive, Personalized and Precision Medicine: A Narrative Review

Cardiovascular disease (CVD) diagnosis and treatment are challenging since symptoms appear late in the disease's progression. Despite clinical risk scores, cardiac event prediction is inadequate, and many at-risk patients are not adequately categorised by conventional risk factors alone. Integrating genomic-based biomarkers (GBBM), specifically those found in plasma and/or serum samples, along with novel non-invasive radiomic-based biomarkers (RBBM) such as plaque area and plaque burden can improve the overall specificity of CVD risk. This review proposes two hypotheses: (i) RBBM and GBBM biomarkers have a strong correlation and can be used to detect the severity of CVD and stroke precisely, and (ii) introduces a proposed artificial intelligence (AI)-based preventive, precision, and personalized ( aiP 3 ) CVD/Stroke risk model. The PRISMA search selected 246 studies for the CVD/Stroke risk. It showed that using the RBBM and GBBM biomarkers, deep learning (DL) modelscould be used for CVD/Stroke risk stratification in the aiP 3 framework. Furthermore, we present a concise overview of platelet function, complete blood count (CBC), and diagnostic methods. As part of the AI paradigm, we discuss explainability, pruning, bias, and benchmarking against previous studies and their potential impacts. The review proposes the integration of RBBM and GBBM, an innovative solution streamlined in the DL paradigm for predicting CVD/Stroke risk in the aiP 3 framework. The combination of RBBM and GBBM introduces a powerful CVD/Stroke risk assessment paradigm. aiP 3 model signifies a promising advancement in CVD/Stroke risk assessment.

Determination of Alzheimer's disease based on morphology and atrophy using machine learning combined with automated segmentation

BACKGROUND

To evaluate the degree of cerebral atrophy for Alzheimer's disease (AD), voxel-based morphometry has been performed with magnetic resonance imaging. Detailed morphological changes in a specific tissue area having the most evidence of atrophy were not considered by the machine-learning technique.

PURPOSE

To develop a machine-learning system that can capture morphology features for determination of atrophy of brain tissue in early-stage AD and classification of healthy participants or patients.

MATERIAL AND METHODS

Three-dimensional T1-weighted (3D-T1W) data were obtained from AD Neuroimaging Initiative (200 healthy controls and 200 patients with early-stage AD). Automated segmentation of 3D-T1W data was performed. Deep learning (DL) and support vector machine (SVM) were trained using 66-segmented volume values as input and AD diagnosis as output. DL was performed using 66 volume values or gray matter (GM) and white matter (WM) volume values. SVM learning was performed using 66 volume values and six regions with high variable importance. 3D convolutional neural network (3D-CNN) was trained using the segmented images. Accuracy and area under curve (AUC) were obtained. Variable importance was evaluated from logistic regression analysis.

RESULTS

DL for GM and WM volume values, accuracy 0.6; SVM for all volume values, accuracy 0.82 and AUC 0.81; DL for all volume values, accuracy 0.82 and AUC 0.8; 3D-CNN using segmental images of the whole brain, accuracy 0.5 and AUC 0.51. SVM using volume values of six regions, accuracy 0.82; image-based 3D-CNN, highest accuracy 0.69.

CONCLUSION

Our results show that atrophic features are more considerable than morphological features in the early detection of AD.

Determination of Significant Three-Dimensional Hemodynamic Features for Postembolization Recanalization in Cerebral Aneurysms Through Explainable Artificial Intelligence

BACKGROUND

Recanalization poses challenges after coil embolization in cerebral aneurysms. Establishing predictive models for postembolization recanalization is important for clinical decision making. However, conventional statistical and machine learning (ML) models may overlook critical parameters during the initial selection process.

METHODS

In this study, we automated the identification of significant hemodynamic parameters using a PointNet-based deep neural network (DNN), leveraging their three-dimensional spatial features. Further feature analysis was conducted using saliency mapping, an explainable artificial intelligence (XAI) technique. The study encompassed the analysis of velocity, pressure, and wall shear stress in both precoiling and postcoiling models derived from computational fluid dynamics simulations for 58 aneurysms.

RESULTS

Velocity was identified as the most pivotal parameter, supported by the lowest P value from statistical analysis and the highest area under the receiver operating characteristic curves/precision-recall curves values from the DNN model. Moreover, visual XAI analysis showed that robust injection flow zones, with notable impingement points in precoiling models, as well as pronounced interplay between flow dynamics and the coiling plane, were important three-dimensional features in identifying the recanalized aneurysms.

CONCLUSIONS

The combination of DNN and XAI was found to be an accurate and explainable approach not only at predicting postembolization recanalization but also at discovering unknown features in the future.

Drop the shortcuts: image augmentation improves fairness and decreases AI detection of race and other demographics from medical images

BACKGROUND

It has been shown that AI models can learn race on medical images, leading to algorithmic bias. Our aim in this study was to enhance the fairness of medical image models by eliminating bias related to race, age, and sex. We hypothesise models may be learning demographics via shortcut learning and combat this using image augmentation.

METHODS

This study included 44,953 patients who identified as Asian, Black, or White (mean age, 60.68 years ±18.21; 23,499 women) for a total of 194,359 chest X-rays (CXRs) from MIMIC-CXR database. The included CheXpert images comprised 45,095 patients (mean age 63.10 years ±18.14; 20,437 women) for a total of 134,300 CXRs were used for external validation. We also collected 1195 3D brain magnetic resonance imaging (MRI) data from the ADNI database, which included 273 participants with an average age of 76.97 years ±14.22, and 142 females. DL models were trained on either non-augmented or augmented images and assessed using disparity metrics. The features learned by the models were analysed using task transfer experiments and model visualisation techniques.

FINDINGS

In the detection of radiological findings, training a model using augmented CXR images was shown to reduce disparities in error rate among racial groups (-5.45%), age groups (-13.94%), and sex (-22.22%). For AD detection, the model trained with augmented MRI images was shown 53.11% and 31.01% reduction of disparities in error rate among age and sex groups, respectively. Image augmentation led to a reduction in the model's ability to identify demographic attributes and resulted in the model trained for clinical purposes incorporating fewer demographic features.

INTERPRETATION

The model trained using the augmented images was less likely to be influenced by demographic information in detecting image labels. These results demonstrate that the proposed augmentation scheme could enhance the fairness of interpretations by DL models when dealing with data from patients with different demographic backgrounds.

FUNDING

National Science and Technology Council (Taiwan), National Institutes of Health.

A deeply supervised adaptable neural network for diagnosis and classification of Alzheimer's severity using multitask feature extraction

Alzheimer's disease is the most prevalent form of dementia, which is a gradual condition that begins with mild memory loss and progresses to difficulties communicating and responding to the environment. Recent advancements in neuroimaging techniques have resulted in large-scale multimodal neuroimaging data, leading to an increased interest in using deep learning for the early diagnosis and automated classification of Alzheimer's disease. This study uses machine learning (ML) methods to determine the severity level of Alzheimer's disease using MRI images, where the dataset consists of four levels of severity. A hybrid of 12 feature extraction methods is used to diagnose Alzheimer's disease severity, and six traditional machine learning methods are applied, including decision tree, K-nearest neighbor, linear discrimination analysis, Naïve Bayes, support vector machine, and ensemble learning methods. During training, optimization is performed to obtain the best solution for each classifier. Additionally, a CNN model is trained using a machine learning system algorithm to identify specific patterns. The accuracy of the Naïve Bayes, Support Vector Machines, K-nearest neighbor, Linear discrimination classifier, Decision tree, Ensembled learning, and presented CNN architecture are 67.5%, 72.3%, 74.5%, 65.6%, 62.4%, 73.8% and, 95.3%, respectively. Based on the results, the presented CNN approach outperforms other traditional machine learning methods to find Alzheimer severity.

Alzheimer's disease prediction algorithm based on de-correlation constraint and multi-modal feature interaction

Alzheimer's disease (AD) is a neurodegenerative disease characterized by various pathological changes. Utilizing multimodal data from Fluorodeoxyglucose positron emission tomography(FDG-PET) and Magnetic Resonance Imaging(MRI) of the brain can offer comprehensive information about the lesions from different perspectives and improve the accuracy of prediction. However, there are significant differences in the feature space of multimodal data. Commonly, the simple concatenation of multimodal features can cause the model to struggle in distinguishing and utilizing the complementary information between different modalities, thus affecting the accuracy of predictions. Therefore, we propose an AD prediction model based on de-correlation constraint and multi-modal feature interaction. This model consists of the following three parts: (1) The feature extractor employs residual connections and attention mechanisms to capture distinctive lesion features from FDG-PET and MRI data within their respective modalities. (2) The de-correlation constraint function enhances the model's capacity to extract complementary information from different modalities by reducing the feature similarity between them. (3) The mutual attention feature fusion module interacts with the features within and between modalities to enhance the modal-specific features and adaptively adjust the weights of these features based on information from other modalities. The experimental results on ADNI database demonstrate that the proposed model achieves a prediction accuracy of 86.79% for AD, MCI and NC, which is higher than the existing multi-modal AD prediction models.

Predicting mild cognitive impairment in older adults: A machine learning analysis of the Alzheimer's Disease Neuroimaging Initiative

AIM

Mild cognitive impairment (MCI) in older adults is potentially devastating, but an accurate prediction model is still lacking. We hypothesized that neuropsychological tests and MRI-related markers could predict the onset of MCI early.

METHODS

We analyzed data from 306 older adults who were cognitive normal (CN) attending the Alzheimer's Disease Neuroimaging Initiative sequentially (474 pairs of visits) within 3 years. There were 231 pairs of MCI conversion (CN to MCI), and 242 pairs of CN maintenance (CN to CN). Variables on demographic, neuropsychological tests, genetic, and MRI-related markers were collected. Machine learning was used to construct MCI prediction models, comparing the area under the receiver operating characteristic curve (AUC) as the primary metric of performance. Important predictors were ranked for the optimal model.

RESULTS

The baseline age of the study sample was 74.8 years old. The best-performing model (gradient boosting decision tree) with 13 variables predicted MCI with an AUC of 0.819, and the rank of variable importance showed that intracranial volume, hippocampal volume, and score from task 4 (word recognition) of the Alzheimer's Disease Assessment Scale were important predictors of MCI.

CONCLUSIONS

With the help of machine learning, fewer neuropsychological tests and MRI-related markers are required to accurately predict MCI within 3 years, thereby facilitating targeted intervention. Geriatr Gerontol Int 2024; 24: 96-101.

A 3D convolutional neural network to classify subjects as Alzheimer's disease, frontotemporal dementia or healthy controls using brain 18F-FDG PET

With the arrival of disease-modifying drugs, neurodegenerative diseases will require an accurate diagnosis for optimal treatment. Convolutional neural networks are powerful deep learning techniques that can provide great help to physicians in image analysis. The purpose of this study is to introduce and validate a 3D neural network for classification of Alzheimer's disease (AD), frontotemporal dementia (FTD) or cognitively normal (CN) subjects based on brain glucose metabolism. Retrospective [18F]-FDG-PET scans of 199 CE, 192 FTD and 200 CN subjects were collected from our local database, Alzheimer's disease and frontotemporal lobar degeneration neuroimaging initiatives. Training and test sets were created using randomization on a 90 %-10 % basis, and training of a 3D VGG16-like neural network was performed using data augmentation and cross-validation. Performance was compared to clinical interpretation by three specialists in the independent test set. Regions determining classification were identified in an occlusion experiment and Gradient-weighted Class Activation Mapping. Test set subjects were age- and sex-matched across categories. The model achieved an overall 89.8 % accuracy in predicting the class of test scans. Areas under the ROC curves were 93.3 % for AD, 95.3 % for FTD, and 99.9 % for CN. The physicians' consensus showed a 69.5 % accuracy, and there was substantial agreement between them (kappa = 0.61, 95 % CI: 0.49-0.73). To our knowledge, this is the first study to introduce a deep learning model able to discriminate AD and FTD based on [18F]-FDG PET scans, and to isolate CN subjects with excellent accuracy. These initial results are promising and hint at the potential for generalization to data from other centers.

Enabling uncertainty estimation in neural networks through weight perturbation for improved Alzheimer's disease classification

Background

The willingness to trust predictions formulated by automatic algorithms is key in a wide range of domains. However, a vast number of deep architectures are only able to formulate predictions without associated uncertainty.

Purpose

In this study, we propose a method to convert a standard neural network into a Bayesian neural network and estimate the variability of predictions by sampling different networks similar to the original one at each forward pass.

Methods

We combine our method with a tunable rejection-based approach that employs only the fraction of the data, i.e., the share that the model can classify with an uncertainty below a user-set threshold. We test our model in a large cohort of brain images from patients with Alzheimer's disease and healthy controls, discriminating the former and latter classes based on morphometric images exclusively.

Results

We demonstrate how combining estimated uncertainty with a rejection-based approach increases classification accuracy from 0.86 to 0.95 while retaining 75% of the test set. In addition, the model can select the cases to be recommended for, e.g., expert human evaluation due to excessive uncertainty. Importantly, our framework circumvents additional workload during the training phase by using our network "turned into Bayesian" to implicitly investigate the loss landscape in the neighborhood of each test sample in order to determine the reliability of the predictions.

Conclusion

We believe that being able to estimate the uncertainty of a prediction, along with tools that can modulate the behavior of the network to a degree of confidence that the user is informed about (and comfortable with), can represent a crucial step in the direction of user compliance and easier integration of deep learning tools into everyday tasks currently performed by human operators.

Diffusion models in bioinformatics and computational biology

Denoising diffusion models embody a type of generative artificial intelligence that can be applied in computer vision, natural language processing and bioinformatics. In this Review, we introduce the key concepts and theoretical foundations of three diffusion modelling frameworks (denoising diffusion probabilistic models, noise-conditioned scoring networks and score stochastic differential equations). We then explore their applications in bioinformatics and computational biology, including protein design and generation, drug and small-molecule design, protein-ligand interaction modelling, cryo-electron microscopy image data analysis and single-cell data analysis. Finally, we highlight open-source diffusion model tools and consider the future applications of diffusion models in bioinformatics.

A Physics-Based Algorithm to Universally Standardize Routinely Obtained Clinical T2-Weighted Images

RATIONALE AND OBJECTIVES

MR images can be challenging for machine learning and other large-scale analyses because most clinical images, for example, T2-weighted (T2w) images, reflect not only the biologically relevant T2 of tissue but also hardware and acquisition parameters that vary from site to site. Quantitative T2 mapping avoids these confounds because it quantitatively isolates the biological parameter of interest, thus representing a universal standardization across sites. However, efforts to incorporate quantitative mapping sequences into routine clinical practice have seen slow adoption. Here we show, for the first time, that the routine T2w complex raw dataset can be successfully regarded as a quantitative mapping sequence that can be reconstructed with classical optimization methods and physics-based constraints.

MATERIALS AND METHODS

While previous constrained reconstruction methods are unable to reconstruct a T2 map based on this data, the expanding-constrained alternating minimization for parameter mapping (e-CAMP), which employs stepwise initialization, a linearized version of the exponential model and a phase conjugacy constraint, is demonstrated to provide useful quantitative maps directly from a vendor T2w single image data.

RESULTS

This paper introduces the method and demonstrates its performance using simulations, retrospectively undersampled brain images, and prospectively acquired T2w images taken on both phantom and brain.

CONCLUSION

Because T2w scans are included in nearly every protocol, this approach could open the door to creating large, standardized datasets without requiring widespread changes in clinical protocols.

Exploring the current and prospective role of artificial intelligence in disease diagnosis

Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems, providing assistance in a variety of patient care and health systems. The aim of this review is to contribute valuable insights to the ongoing discourse on the transformative potential of AI in healthcare, providing a nuanced understanding of its current applications, future possibilities, and associated challenges. The authors conducted a literature search on the current role of AI in disease diagnosis and its possible future applications using PubMed, Google Scholar, and ResearchGate within 10 years. Our investigation revealed that AI, encompassing machine-learning and deep-learning techniques, has become integral to healthcare, facilitating immediate access to evidence-based guidelines, the latest medical literature, and tools for generating differential diagnoses. However, our research also acknowledges the limitations of current AI methodologies in disease diagnosis and explores uncertainties and obstacles associated with the complete integration of AI into clinical practice. This review has highlighted the critical significance of integrating AI into the medical healthcare framework and meticulously examined the evolutionary trajectory of healthcare-oriented AI from its inception, delving into the current state of development and projecting the extent of reliance on AI in the future. The authors have found that central to this study is the exploration of how the strategic integration of AI can accelerate the diagnostic process, heighten diagnostic accuracy, and enhance overall operational efficiency, concurrently relieving the burdens faced by healthcare practitioners.